HomeScience & ExplorationTop 10 Countries by Per Capita Healthcare R&D Expenditure
Top 10Updated 2026年3月15日

Top 10 Countries by Per Capita Healthcare R&D Expenditure

This ranking evaluates global healthcare R&D investment intensity as of 2026. It reflects the dedication and strategic focus of nations on life sciences, biopharmaceuticals, and medical technology innovation by measuring annual per capita research expenditure.

Current #1
Switzerland

Interesting Facts & Summary

In the 2026 global R&D landscape, Switzerland once again holds the top spot for per capita medical R&D expenditure, cementing its status as the 'Silicon Valley of Life Sciences.'

  • Investment Scale: Switzerland’s per capita expenditure is roughly 8 times the global average. The core engine is its dense biopharmaceutical ecosystem, anchored by global giants like Roche and Novartis.
  • Comparative Analysis: While the U.S. drives innovation through a massive healthcare market, Switzerland excels through a remarkably high GDP-to-R&D conversion rate. Despite a population of only 9 million, its medical R&D output rivals that of economies with ten times its size.
  • Key Facts: Switzerland boasts one of the highest densities of patent filings globally. With over 70% of R&D funding sourced from the private sector, this 'high-output, strong-incentive' model keeps the nation at the forefront of breakthroughs in oncology and gene editing.
RankCountryPer Capita Expenditure (USD)Core R&D Focus
Switzerland
1850Pharmaceuticals and Biotechnology
United States
1620Precision Medicine and Oncology
Denmark
1380Metabolic Diseases and Life Sciences
4
Singapore
1250Medical Robotics and Digital Health
5
Sweden
1190Clinical Medicine and Genetics
6
Germany
1120Biomanufacturing and Medical Devices
7
Netherlands
1080Medical Imaging and Public Health Tech
8
United Kingdom
1050Genomics and Immunotherapy
9
Norway
980Telemedicine and Rehabilitation Tech
10
Israel
950AI Diagnostics and Health Startups

List Stats

Views6
Items10
CategoryScience & Exploration

Comments

No comments yet. Be the first to comment!